Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...